Division of Surgical Oncology, Department of Surgery, Arthur G. James Cancer Hospital, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.
World J Surg Oncol. 2011 Nov 23;9:152. doi: 10.1186/1477-7819-9-152.
(18)F-FDG PET/CT is widely utilized in the management of cancer patients. The aim of this paper was to comprehensively describe the specific methodology utilized in our single-institution cumulative retrospective experience with a multimodal imaging and detection approach to (18)F-FDG-directed surgery for known/suspected malignancies.
From June 2005-June 2010, 145 patients were injected with (18)F-FDG in anticipation of surgical exploration, biopsy, and possible resection of known/suspected malignancy. Each patient underwent one or more of the following: (1) same-day preoperative patient diagnostic PET/CT imaging, (2) intraoperative gamma probe assessment, (3) clinical PET/CT specimen scanning of whole surgically resected specimens (WSRS), research designated tissues (RDT), and/or sectioned research designated tissues (SRDT), (4) micro PET/CT specimen scanning of WSRS, RDT, and/or SRDT, (5) total radioactivity counting of each SRDT piece by an automatic gamma well counter, and (6) same-day postoperative patient diagnostic PET/CT imaging.
Same-day (18)F-FDG injection dose was 15.1 (± 3.5, 4.6-26.1) mCi. Fifty-five same-day preoperative patient diagnostic PET/CT scans were performed. One hundred forty-two patients were taken to surgery. Three of the same-day preoperative patient diagnostic PET/CT scans led to the cancellation of the anticipated surgical procedure. One hundred forty-one cases utilized intraoperative gamma probe assessment. Sixty-two same-day postoperative patient diagnostic PET/CT scans were performed. WSRS, RDT, and SRDT were scanned by clinical PET/CT imaging and micro PET/CT imaging in 109 and 32 cases, 33 and 22 cases, and 49 and 26 cases, respectively. Time from (18)F-FDG injection to same-day preoperative patient diagnostic PET/CT scan, intraoperative gamma probe assessment, and same-day postoperative patient diagnostic PET/CT scan were 73 (± 9, 53-114), 286 (± 93, 176-532), and 516 (± 134, 178-853) minutes, respectively. Time from (18)F-FDG injection to scanning of WSRS, RDT, and SRDT by clinical PET/CT imaging and micro PET/CT imaging were 389 (± 148, 86-741) and 458 (± 97, 272-656) minutes, 619 (± 119, 253-846) and 661 (± 117, 433-835) minutes, and 674 (± 186, 299-1068) and 752 (± 127, 499-976) minutes, respectively.
Our multimodal imaging and detection approach to (18)F-FDG-directed surgery for known/suspected malignancies is technically and logistically feasible and may allow for real-time intraoperative staging, surgical planning and execution, and determination of completeness of surgical resection.
(18)F-FDG PET/CT 广泛应用于癌症患者的管理中。本文的目的是全面描述我们在单机构累积回顾性经验中使用的特定方法,该经验采用多模态成像和检测方法,对已知/疑似恶性肿瘤进行(18)F-FDG 引导的手术。
从 2005 年 6 月至 2010 年 6 月,145 名患者在预期进行手术探查、活检和可能切除已知/疑似恶性肿瘤之前注射了(18)F-FDG。每位患者接受了以下一项或多项检查:(1)同一天的术前患者诊断 PET/CT 成像;(2)术中伽马探针评估;(3)对整个手术切除标本(WSRS)、研究指定组织(RDT)和/或切片研究指定组织(SRDT)进行临床 PET/CT 标本扫描;(4)对 WSRS、RDT 和/或 SRDT 进行微 PET/CT 标本扫描;(5)通过自动伽马井计数器对每个 SRDT 块进行总放射性计数;(6)同一天的术后患者诊断 PET/CT 成像。
同一天注射的(18)F-FDG 剂量为 15.1(±3.5,4.6-26.1)mCi。进行了 55 次同一天的术前患者诊断 PET/CT 扫描。142 名患者接受了手术。三次同一天的术前患者诊断 PET/CT 扫描导致取消了预期的手术程序。141 例患者使用了术中伽马探针评估。进行了 62 次同一天的术后患者诊断 PET/CT 扫描。WSRS、RDT 和 SRDT 分别在 109 例和 32 例、33 例和 22 例以及 49 例和 26 例患者中通过临床 PET/CT 成像和微 PET/CT 成像进行了扫描。从(18)F-FDG 注射到同一天的术前患者诊断 PET/CT 扫描、术中伽马探针评估和同一天的术后患者诊断 PET/CT 扫描的时间分别为 73(±9,53-114)、286(±93,176-532)和 516(±134,178-853)分钟。从(18)F-FDG 注射到 WSRS、RDT 和 SRDT 的临床 PET/CT 成像和微 PET/CT 成像扫描的时间分别为 389(±148,86-741)和 458(±97,272-656)分钟、619(±119,253-846)和 661(±117,433-835)分钟以及 674(±186,299-1068)和 752(±127,499-976)分钟。
我们对已知/疑似恶性肿瘤的(18)F-FDG 引导手术的多模态成像和检测方法在技术和后勤上是可行的,并且可能允许实时术中分期、手术计划和执行以及确定手术切除的完整性。